

DRUGS UNDER REVIEW

This list contains provider-administered drugs that are newly approved by the Food and Drug Administration (FDA). Drugs on this list are being evaluated by PreferredOne for safety, efficacy, and coverage consideration. Completion of review and decision of coverage will be made within 12 months of FDA approval. Prior to review and decision, these medications will not be covered. For more information, see Pharmacy Policy PP/R001 – Review of New FDA-Approved Drugs and Clinical Indications.

DRUG TRADE NAME	TARGET INDICATION	FDA APPROVAL	REMOVAL FROM LIST
Amvuttra (vutrisiran)	Polyneuropathy of Hereditary Transthyretin - mediated amyloidosis in adults	6/13/2022	6/13/2023
Cimerli (ranibizumab-eqrn)	Wet AMD; Macular edema; Diabetic macular edema; Diabetic retinopathy; choroidal neovascularization, myopic	8/2/2022	8/2/2023
Zynteglo (betibeglogene autotemcel)	Transfusion-dependent beta-thalassemia (TDT)	8/17/2022	8/17/2023
Xenpozyme (olipudase alfa)	Acid sphingomyelinase deficiency (ASMD)	8/31/2022	8/31/2023
Spevigo (spesolimab-sbzo)	flares of generalized pustular psoriasis	9/1/2022	9/1/2023

9.26.2022